Videos

Advancing Outcomes in Metastatic Pancreatic Cancer

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.

General Cancer

Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses results from the phase III OPTIMISMM trial comparing treatment regimens for relapsed/refractory multiple myeloma. This data compares a regimen of pomalidomide, bortezomib, and dexamethasone versus bortezomib and dexamethasone alone. 

Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.

Breast Cancer

Thierry Andre, MD, professor of medical oncology at the University Pierre et Marie Curie (UMPC) and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux in Paris, discusses the introduction of immunotherapy to the treatment landscape of metastatic colorectal cancer.

W. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer.